临床专家

元云飞

职称：二级教授、一级主任医师、博士生导师

专长

原发性肝癌的外科治疗、介入治疗、靶向免疫治疗；结直肠癌肝转移的外科治疗和局部治疗。

一、基本情况

　　职务：无

　　职称：二级教授、一级主任医师、博士生导师

　　专家门诊时间： 周一上午，周四上午，周五上午

　　专业特长：主要从事原发性肝癌的外科治疗、介入治疗、靶向免疫治疗和结直肠癌肝转移的外科治疗、局部治疗。在中国率先应用ICGR15评估肝储备功能，熟练掌握各种复杂的肝脏恶性肿瘤切除手术。

 

二、学习及工作经历

1978年—1983年：中山医学院医学系，获学士学位

1983年—1986年：中国医学科学院血液学研究所工作

1986年—1989年：中山医科大学外科学硕士研究生，获医学硕士学位

1989年—1998年：中山大学附属肿瘤医院工作

1998年—2000年：Baylor医学院进修学习

2000年—2001年：美国MD Anderson癌症中心进修学习

2001年至今：中山大学附属肿瘤医院肝脏外科工作

 

华南恶性肿瘤防治全国重点实验室PI

《Cancer Communications》杂志(原癌症杂志)编委（2003.01-至今）

《中华普通外科学文献(电子版)》杂志编委（2007.08-至今）

《中华肝脏外科手术学电子杂志》编委（2012.12-至今）

中国医师协会外科医师分会肝脏外科专家工作组专家委员（2023.7-2026.6）

国际肝胆胰协会中国分会首届肝脏肿瘤专业委员会常务委员（2024.10.25-2028.10.24）

广东省抗癌协会肿瘤转移专业委员会第三届委员会主任委员 （2023.4-2027.7）

广东省临床医学学会肝癌与肝转移瘤专业委员会第一届主任委员 (2020.11.28- 2025.11.27)

加载更多

1983年毕业于中山医学院，获学士学位。1983年9月至1986年8月在天津市中国医学科学院血液学研究所工作。1986年9月回母校读研究生，师从著名外科学家王吉甫教授（已故），1989年8月毕业，获医学硕士学位。1989年9月起在中山（医科）大学肿瘤医院腹科或肝胆科或肝脏外科工作，其中1998.8-2001.8在美国进修学习。1991年晋升为主治医师，1997年晋升为副教授，2004年破格晋升为研究员，2006年转聘为教授、主任医师，并获得博士生导师资格。2014年8月聘为中山大学三级教授、二级主任医师。2023年1月聘为中山大学二级教授、二级研究员、一级主任医师。2006年11月至2023年1月任肝胆胰科或肝脏外科副主任。2023年入选第六届国之名医·卓越建树。

主要从事肝癌的外科治疗和综合治疗（包括介入治疗、靶向治疗、免疫治疗等）和结直肠癌肝转移的外科治疗和局部治疗。2003年9月开展肝移植治疗肝癌。肝移植的开展大大提高了肝外科的手术水平，肝切除术已无手术禁区。熟练掌握各种复杂的肝切除术。临床工作认真负责，外科技术娴熟，手术精细。

在国内较早开展肝储备功能的研究，1992年开始应用吲哚靛青绿15分钟储留率（ICGR15）单一指标术前评估肝癌病人肝储备功能，明显降低了肝癌切除术后肝功能衰竭发生率[中华肿瘤杂志1995，17:377]，提出ICGR15评估肝癌病人肝储备功能具有简便、实用、较准确等特点。1997年首次提出对于不能切除的肝癌行肝动脉化疗栓塞，若肝储备功能良好，应使用较大剂量lipiodol栓塞，让lipiodol尽量填满肿瘤，达到肿瘤最大限度坏死，而不出现肝功能衰竭[癌症16:358和癌症16(增刊):39]。

积极开展肝癌的临床研究，如肝癌合并门静脉高压的治疗策略；肝癌的转化治疗，通过肝动脉栓塞灌注化疗（TACE+HAIC），联合免疫、靶向治疗等，使部分不可切除或不宜切除的肝癌转化为可手术切除，明显提高了中晚期肝癌的治疗效果，并在全国多地积极推广“中肿方案”。首次提出肝癌经转化治疗后达到临床完全缓解（cCR）,可选择观察与等待（Watch and Wait）策略。

积极开展结直肠癌肝转移的外科治疗和临床研究。2012年7月在法国巴黎较系统学习结直肠肝转移外科治疗为主的治疗策略。本院结直肠癌肝转移的综合治疗在全国具有很好的声誉，大部分结直肠癌肝转移的外科治疗由本医疗组完成。

受国家卫生部推荐，于1998年获得世界卫生组织奖学金。作为访问学者，1998.9-2000.7在美国Baylor医学院进修，2000.8-2001.8在美国M.D. Anderson癌症中心进修。学习肿瘤分子生物学与肝胆肿瘤的外科治疗等。国际上首次发现SYK基因的不表达是由其启动子过甲基化引起（Cancer Research 2001, 61:5558）。2001年8月回国后，继续开展肿瘤分子生物学的研究，医院给本课题组配备了独立的肝癌分子生物学实验室和研究助理等，获得多项国家自然科学基金。作为（共同）第一或（共同）通讯作者，论文发表在The Journal of Clinical Oncology, The Journal of Clinical Investigation, Gastroenterology, Hepatology, Gut, Cancer Research, Clinical Cancer Research, Oncogene, Advanced Science, Nature Communications等国际知名杂志。

精心培养研究生，二位博士研究生分别获得2013年广东省优秀博士学位论文和2023年中山大学优秀博士学位论文。已毕业的研究生留在本院工作，或录取到中山大学其他附属医院，或在广东、北京、山东、湖南、江西等地三甲医院工作，部分毕业的博士研究生已成为博士研究生导师，并担任国内知名三甲医院的科室主任。

 

部分科研基金：

(1) 国家自然科学基金，面上项目， USP14诱导肿瘤细胞糖代谢重编程调控肝癌免疫治疗抵抗及其机制研究，项目负责人：元云飞，项目编号：82272887，52.00万元, 2023.01～2026.12

(2) 国家自然科学基金面上项目，S100A9通过EMT调控肝细胞癌侵袭转移的机制研究 ，项目负责人：元云飞，项目编号：81972301，经费（直接费用）：55.00万元，2020.01～2023.12

(3) 国家自然科学基金面上项目，Elafin通过EGFR/ERK信号通路调控肝细胞癌侵袭转移的机制研究，项目负责人：元云飞，项目编号：81772598，经费(直接费用)：65万人民币，2018.01～2021.12。

(4) 国家自然科学基金面上项目，Rfx6在肝癌干细胞干性特征维持中的作用及机制研究，项目负责人：元云飞，项目编号：81372571，经费：90万人民币，2014.01～2017.12。

(5) 国家自然科学基金面上项目，肝癌Chk1/SYK(L)通路与靶向治疗，项目负责人：元云飞，项目编号：81172344，经费：69万人民币，2012.01～2015.12。

(6) 国家自然科学基金面上项目，Chk1 参与肝癌Syk(L)和Syk(S)的表达调控及机制研究，项目负责人：元云飞，项目编号：30972916，经费：32万人民币，2010.01～2012.12。

(7) 国家自然科学基金面上项目，SYK 作为肝癌复发转移标志物的研究，项目负责人：元云飞，项目编号：30872489，经费：30万人民币，2009.01～2011.12。

(8) 国家自然科学基金专项基金项目（科学部主任基金），SYK 基因与肝细胞癌侵袭性的研究，项目负责人：元云飞，项目编号：30540047，经费：8万人民币，2006.01～2006.12。

(9) 广东省自然科学基金重点项目，PI3基因抑制肝细胞癌侵袭转移的分子机制，项目编号： 2017A030311006，经费：50万人民币，2017.05～2020.05

(10) 广州市科技计划项目重点项目专题， Rfx6促进肝细胞癌侵袭转移的机制研究，项目编号: 201804020093，经费： 200万人民币，2018.05～2021.04

(11) 国家重点基础研究发展计划（973计划），肿瘤异质性演化机制与个体治疗策略的生物学研究，项目首席科学家:吴仲义，分题骨干，经费：62.5万，2014.01～2018.12

(12) 中山大学临床医学研究5010计划项目，精准肝切除与综合介入治疗方案治疗肝细胞肝癌合并肝硬化门静脉高压症的临床随机对照研究，项目负责人：元云飞，经费：200 万人民币，2012 .07～2022.7

(13) 中山大学（985工程）转化医学研究示范性项目，早期肝癌复发转移相关DNA甲基化表型的筛选和预测体系的建立，项目负责人：元云飞，经费：100万人民币，2011～2013。

(14) 广东省高等学校科技创新重点项目（广东省教育厅），肝细胞肝癌合并肝硬化门静脉高压症的治疗策略，项目负责人：元云飞，项目编号：CXZD1133，经费：25万人民币，2012.1～2014.12。

(15) 985-II 工程项目课题，肝细胞癌肿瘤相关基因甲基化的研究，项目负责人：元云飞，经费：30万人民币，2006.1-2007.12

(16) 美国中华医学基金会(China Medical Board of New York, Inc.)，“SYK gene methylation, SYK protein expression, and Hepatocellular carcinoma invasion.” 课题负责人（PI）：元云飞, No: 98-677, US$ 70 000，2003.1～2004.12.   

(17) 广东省科技厅科技计划项目，肿瘤侵袭性相关基因的过甲基化作为肝癌复发转移标志物的研究，项目负责人：元云飞，项目编号：2002B30107，经费：15万民币，2003.1～2005.12。

 

部分论文：

Peer-Reviewed Original Research Articles (* as correspondence author):

  1. Yunfei Yuan, Richard Mendez, Aysegul Sahin, and Jia Le Dai*. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Research 2001, 61(14):5558-5561. (2001 IF=8.302)
  2. Yunfei Yuan, Hongji Liu, Aysegul Sahin and Jia Le Dai*. Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. International Journal of Cancer 2005, 113(4):654–659. (2005 IF=4.7)
  3. Yunfei Yuan*, Jianping Wang, Jinqing Li, Li Wang, Meixiang Li, Zuli Yang, Changqing Zhang, and Jia Le Dai.  Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clinical Cancer Research 2006, 12(22):6687-6695. (2006 IF=6.177)
  4. Li Xu, Liang Huang, Bin-kui Li, Ya-qi Zhang, Jin-qing Li, Yun-fei Yuan*. Clinicopathologic Features and Long-Term Outcomes of Chinese Patients with Hepatocellular Carcinoma in Non-Cirrhotic Liver. Digestive Surgery 2008, 25(5):376. (2008 IF=1.257)
  5. Hang Su, Jian-Rong Yang, Teng Xu, Jun Huang, Li Xu, Yunfei Yuan*, Shi-Mei Zhuang*. MicroRNA-101, Downregulated in Hepatocellular Carcinoma, Promotes Apoptosis and Suppresses Tumorigenicity. Cancer Research 2009, 69(3):1135-42. (2009 IF=7.543)
  6. Jun Huang, Bin-Kui Li, Gui-Hua Chen, Jin-Qing Li, Ya-Qi Zhang, Guo-Hui Li, Yun-fei Yuan*. Long-Term Outcomes and Prognostic Factors of Elderly Patients with Hepatocellular Carcinoma Undergoing Hepatectomy. Journal of Gastrointestinal Surgery 2009, 13(9):1627-1635. (2009 IF=2.402)
  7. Binkui Li, Wenji Liu, Li Wang, Meixiang Li, Jianping Wang, Liang Huang, Pinzhu Huang, and Yunfei Yuan*. CpG Island Methylator Phenotype Associated with Tumor Recurrence in Tumor-Node-Metastasis Stage I Hepatocellular Carcinoma. Annals of Surgical Oncology, 2010, 17(7):1917-1926. (2010 IF=4.182)
  8. Binkui Li, Yunfei Yuan*, Guihua Chen, Liru He, Yaqi Zhang, Jinqing Li, Guohui Li, and Wan Yee Lau. Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome? BMC Cancer. 2010, 10:535-43. (2010 IF=3.153)
  9. Liang Huang, Mei-Xiang Li, Li Wang, Bin-Kui Li, Gui-Hua Chen, Li-Ru He, Li Xu, Yun-Fei Yuan*. Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation. Tumor Biology 2011, 32:233-240. (2011 IF=2.143)
  10. Leilei Chen, Yun-Fei Yuan(co-first), Yan Li, Tim Hon Man Chan, Bo-Jian Zheng, Jun Huang, Xin-Yuan Guan*. Clinical significance of CHD1L in hepatocellular carcinoma and therapeutic potentials of virus-mediated CHD1L depletion. Gut 2011, 60(4):534-43. (2011 IF=10.111)
  11. Pinzhu Huang, Jiliang Qiu, Binkui Li, Jian Hong, Canliang Lu, Li Wang, Jianping Wang, Yezhu Hu, Weihua Jia, Yunfei Yuan*. Role of Sox2 and Oct4 in predicting survival of hepatocellular carcinoma patients after hepatectomy. Clinical Biochemistry 2011, 44:582-589. (2011 IF=2.076)
  12. Jiliang Qiu, Pinzhu Huang, Qian Liu, Jian Hong, Binkui Li, Canliang Lu, Li Wang, Jianping Wang and Yunfei Yuan*. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. Journal of Translational Medicine 2011, 9:166. (2011 IF=3.474)
  13. Can-Liang Lu, Ji-Liang Qiu, Pin-Zhu Huang, Ru-Hai Zou, Jian Hong, Bin-Kui Li, Gui-Hua Chen, Yunfei Yuan*. NADPH Oxidase DUOX1 and DUOX2 but not NOX4 are independent predictors in hepatocellular carcinoma after hepatectomy. Tumor Biology 2011, 32(6):1173-1182. (2011 IF=2.143)
  14. Jian Hong, Kaishun Hu, Yunfei Yuan*, Yi Sang, Qiangui Bu, Guihua Chen, Longjun Yang, Binkui Li, Pinzhu Huang, Dongtai Chen, Yi Liang, Ruhua Zhang, Jingxuan Pan, Yi-Xin Zeng, and Tiebang Kang*. CHK1 targets spleen tyrosine kinase(L) for proteolysis in hepatocellular carcinoma. The Journal of Clinical Investigation 2012, 122(6):2165-2175. (2012 IF=12.812)
  15. Qing-an Zeng, Jiliang Qiu, Jian Hong, Yi Li, Shengping Li, Ruhai Zou, Pinzhu Huang, Binkui Li, Yun Zheng, Xiangming Lao and Yunfei Yuan*. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis. European Journal of Gastroenterology & Hepatology. 2012, 24(5):575-82. (2012 IF=1.915)
  16. Qing-An Zeng, Jiliang Qiu, Ruhai Zou, Yijie Li, Shengping Li, Binkui Li, Pinzhu Huang, Jian Hong, Yun Zheng, Xiangming Lao, Yunfei Yuan*. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study. BMC Cancer 2012, 12(1):148. (2012 IF=3.333)
  17. Ru-hai Zou, An-hua Li, Feng Han, Jiang Hong, Bin-kui Li, Wei Huang, Liang Huang, Yun-fei Yuan*. Liver hypertrophy and accelerated growth of implanted tumors in nonembolized liver of rabbit after left portal vein embolization. Journal of Surgical Research 2012, 178:256-263 (2012 IF=2.018)
  18. Ji-Liang Qiu, Pin-Zhu Huang, Jing-Hong You, Ru-Hai Zou, Li Wang, Jian Hong, Bin-Kui Li, Kai Zhou, and Yun-fei Yuan*. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chinese Journal of Cancer 2012, 31(5):223-232. (2014, IF=2.155)
  19. Yan Li, Leilei Chen, Tim Hon Man Chan, Ming Liu, Kar–Lok Kong, Ji–Liang Qiu, Yan Li, Yun–Fei Yuan*, and Xin–Yuan Guan*. SPOCK1 Is Regulated by CHD1L and Blocks Apoptosis and Promotes HCC Cell Invasiveness and Metastasis in Mice. Gastroenterology 2013, 144:179-191  （2013 IF=13.926）
  20. J.-L. Qiu, M.-G. Deng, W Li, R.-H. Zou, B.-K. Li, Y Zheng, X.-M. Lao, K Zhou, Y.-F. Yuan*. Hepatic Resection for Synchronous Hepatic Metastasis from Gastric Cancer. European Journal of Surgical Oncology 2013, 39:694-700 (2013 IF=2.843)
  21. Ruizhi Wang, Na Zhao, Siwen Li, Jian-Hong Fang, Mei-Xian Chen, Jine Yang, Wei-Hua Jia, Yunfei Yuan* and Shi-Mei Zhuang*. MicroRNA-195 Suppresses Angiogenesis and Metastasis of Hepatocellular Carcinoma by Inhibiting the Expression of VEGF, VAV2, and CDC42. Hepatology 2013, 58(2):642-53. （2013 IF=11.19）
  22. J Gong, J-P Zhang, B Li, C Zeng, K You, M-X Chen, Y Yuan* and S-M Zhuang*. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene 2013, 32(25):3071-9. （2013 IF=8.559）
  23. Rongrong Wei, Guo-Liang Huang, Mei-Yin Zhang, Bin-Kui Li, Hui-Zhong Zhang, Ming Shi, Xiao-Qian, Chen, Long Huang, Qing-Ming Zhou, Wei-Hua Jia, X.F. Steven Zheng, Yun-Fei Yuan*, and Hui-Yun Wang*. Clinical Significance and Prognostic Value of microRNA Expression Signatures in Hepatocellular Carcinoma. Clinical Cancer Research 2013, 19(17): 1–12. （2013 IF=8.193）
  24. Jian Hong, Yunfei Yuan*, Jianping Wang, Yadi Liao, Ruhai Zou, Chuanlong Zhu, Binkui Li, Yi Liang, Pinzhu Huang, Zongwei Wang, Wenyu Lin, Yixin Zeng, Jia Le Dai, and Raymond T. Chung*. Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma. Cancer Research 2014, 74(6):1845-56 (2014 IF=9.329)
  25. Binkui Li, Pinzhu Huang, Jiliang Qiu, Yadi Liao, Jian Hong, Yunfei Yuan*. MicroRNA-130a is down-regulated in hepatocellular carcinoma and associates with poor prognosis. Medical Oncology, 2014, 31(10): 230. (2014 IF=2.634)
  26. Jun Huang, Qijiong Li, Yun Zheng, Jingxian Shen, Jiliang Qiu, Binkui Li, Ruhai Zou, Jianping Wang and Yunfei Yuan*. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature. BMC Cancer 2014, 14:818. (2014 IF=3.362)
  27. Bin-Kui Li, Pin-Zhu Huang, Ji-Liang Qiu, Ya-Di Liao, Jian Hong and Yun-Fei Yuan*. Upregulation of microRNA-106b is associated with poor prognosis in hepatocellular carcinoma. Diagnostic Pathology 2014, 9:226. (2014 IF=2.597)
  28. Wei He, Qingli Zeng, Yun Zheng, Meixian Chen, Jingxian Shen, Jiliang Qiu, Miao Chen,  Ruhai Zou, Yadi Liao, Qijiong Li, Xianqiu Wu, Binkui Li* and Yun-Fei Yuan*. The role of clinically significant portal hypertension in hepatic resection for hepatocellular carcinoma patients: a propensity score matching analysis. BMC Cancer 2015, 15:263. (2015 IF=3.265)
  29. Xianqiu Wu, Binkui Li, Jiliang Qiu, Jingxian Shen, Yun Zheng, Qijong Li, Yadi Liao, Wei He, Ruhai Zou and Yunfei Yuan*. Hepatectomy versus hepatectomy with lymphadenectomy in hepatocellular carcinoma – A prospective, randomized controlled clinical trial. Journal of Clinical Gastroenterology 2015;49:520-528（2015 IF=3.163）
  30. Jiliang Qiu, Yun Zheng, Jingxian Shen, Zeng QingAn, Ruhai Zou, Yadi Liao, Wei He, Qijiong Li, Guihua Chen, Binkui Li, Yunfei Yuan*. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study. Surgery. 2015, 158(5):1235-1243.（2015 IF=3.309）
  31. Pinghua Yang, Jiliang Qiu, Jun Li, Dong Wu, Xuying Wan, Wan Yee Lau, Yunfei Yuan*, and Feng Shen*. Nomograms for Pre- and Postoperative Prediction of Long-term Survival for Patients Who Underwent Hepatectomy for Multiple Hepatocellular Carcinomas. Annals of Surgery. 2016, 263(4):778-86. (2016 IF=8.98) 
  32. Pinzhu Huang, Chunhong Liu,  Binkui Li,  Yun Zheng,  Ruhai Zou, Jun Huang,  Zemin Hu, Yunfei Yuan*. Preoperative mean corpuscular hemoglobin affecting longterm outcomes of hepatectomized patients with hepatocellular carcinoma. Molecular and Clinical Oncology 2016, 4: 229-236.
  33. Wei He, Binkui Li, Yun Zheng, Ruhai Zou, Meixian Chen, Jingxian Shen, Donghui Cheng, Qiang Tao, Wenwu Liu, Qijiong Li, Guihua Chen and Yunfei Yuan*. Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver International 2016, 36(11):1677-1687(2016 IF=4.116)
  34. Jiliang Qiu, Baogang Peng, Yunqiang Tang, Yeben Qian, Pi Guo, Mengfeng Li, Junhang Luo, Bin Chen, Hui Tang, Canliang Lu, Muyan Cai, Zunfu Ke, Wei He, Yun Zheng, Dan Xie, Binkui Li*, and Yunfei Yuan*. A CpG Methylation Signature Predicts Recurrence in Early-Stage Hepatocellular Carcinoma: Results From a Multicenter Study. Journal of Clinical Oncology 2017, 35(7):734-742  (2017 IF=26.303)
  35. Yadi Liao, Yun Zheng, Wei He, Qijiong Li, Jingxian Shen, Jian Hong, Ruhai Zou, Jiliang Qiu, Binkui Li* , Yunfei Yuan*. Sorafenib therapy following resection prolongs diseasefree survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence.  Oncology Letters 2017, 13: 984-992. (2017 IF=1.664) 
  36. Binkui Li*, Liru He, Dinglan Zuo, Wei He, Yongjin Wang, Yuanping Zhang, Wenwu Liu and Yunfei Yuan*. Mutual Regulation of MiR-199a-5p and HIF-1αModulates the Warburg Effect in Hepatocellular Carcinoma. Journal of Cancer 2017, 8:940-949. (2016 IF=3.249)
  37. Wei He, Baogang Peng, Yunqiang Tang, Junpin Yang, Yun Zheng, Jiliang Qiu, Ruhai Zou, Jingxian Shen, Binkui Li*, Yunfei Yuan*. Nomogram to Predict Survival of Patients with Recurrence of Hepatocellular Carcinoma After Surgery. Clinical Gastroenterology and Hepatology 2018, 16:756–764  (2018 IF=7.958)
  38. Wei He, Yun Zheng, Ruhai Zou, Jingxian Shen, Junpin Yang, Jiliang Qiu, Qiang Tao, Wenwu Liu, Zhiwen Yang, Yuanping Zhang, Binkui Li*, Yunfei Yuan*. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Communications (Lond). 2018, 38(1):26. (2018 IF=3.620)
  39. Qiang Tao, Wei He, Binkui Li, Yun Zheng,, Ruhai Zou, Jingxian Shen, Wenwu Liu, Yuanping Zhang, Yunfei Yuan*. Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence. Journal of Cancer 2018, 9(16), 2778–2785. (2018 IF=3.182)
  40. Zhi-Wen Yang, Wei He, Yun Zheng, Ru-Hai Zou, Wen-Wu Liu, Yuan-Ping Zhang, Chen-Wei Wang, Yong-Jin Wang, Yi-Chuan Yuan, Bin-Kui Li*, Yun-Fei Yuan*. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. Journal of Cancer. 2018, 9(21):4000-4008. (2018 IF=3.182)
  41. Wenwu Liu, Yun Zheng, Wei He, Ruhai Zou, Jiliang Qiu, Jingxian Shen, Zhiwen Yang, Yuanping Zhang, Chenwei Wang, Yongjin Wang, Dinglan Zuo, Binkui Li*, Yunfei Yuan*. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Alimentary Pharmacology & Therapeutics 2018, 48(6):671-681. (2018 IF=7.731)
  42. Wenwu Liu, Yun Zheng, Ruhai Zou, Jingxian Shen, Wei He, Zhiwen Yang, Yuanping Zhang, Binkui Li* and Yunfei Yuan*. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018, 18:1186 (2018 IF=2.933)
  43. Jian-Hong Fang*, Zi-Jun Zhang, Li-Ru Shang, Yu-Wei Luo, Yi-Fang Lin, Yunfei Yuan*, and Shi-Mei Zhuang*. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 2018, 68(4):1459-1475.  (2018 IF=14.971)
  44. Zhiwen Yang, Ruhai Zou, Yun Zheng, Jiliang Qiu, Jingxian Shen, Yadi Liao, Yuanping Zhang, Chenwei Wang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo & Wei He, Wenwu Liu, Binkui Li*, Yunfei Yuan*. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. European Radiology 2019, 29:5752–5762 (2018 IF=3.962)
  45. Wenwu Liu, Zhiwen Yang, Ruhai Zou, Jiliang Qiu, Jingxian Shen, Yadi Liao, Chenwei Wang, Yuanping Zhang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo, Wei He, Yun Zheng*, Binkui Li*, Yunfei Yuan*. Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. Journal of Cancer 2019; 10(13):2857-2867. (2018 IF=3.182)
  46. Wenwu Liu, Ruhai Zou, Chenwei Wang, Jiliang Qiu, Jingxian Shen, Yadi Liao, Zhiwen Yang, Yuanping Zhang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo, Wei He, Yun Zheng, Binkui Li and Yunfei Yuan*. Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Therapeutic Advances in Medical Oncology 2019, 11: 1–13 (2019 IF= 6.852)
  47. Chenwei Wang, Wei He, Yichuan Yuan, Yuanping Zhang, Kai Li, Ruhai Zou, Yadi Liao, Yongjin Wang,, Wenwu Liu,  Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Yun Zheng, Binkui Li*, Yunfei Yuan*. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy.  Liver International 2020, 40(1):229-239 (2019 IF=5.175)
  48. Chenwei Wang, Yadi Liao, Jiliang Qiu, Yichuan Yuan, Yuanping Zhang, Kai Li,  Ruhai Zou1, Yongjin Wang, Dinglan Zuo, Wei He, Yun Zheng, Binkui Li*, Yunfei Yuan*. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. Journal of Cancer Research and Clinical Oncology 2020,146(10):2669-2680. (2019 IF=3.656)
  49. Yadi Liao, Chenwei Wang, Zhiwen Yang, Wenwu Liu, Yichuan Yuan, Kai Li, Yuanping Zhang, Yongjin Wang, Yunxing Shi, Yuxiong Qiu, Dinglan Zuo, Wei He, Jiliang Qiu, Xinyuan Guan, Yunfei Yuan*, Binkui Li*. Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics. 2020, 10(12):5209-5224.
  50. Yuanping Zhang, Yongjin Wang, Yichuan Yuan, Jiliang Qiu, Yuxiong Qiu, Wei He, Yun Zheng, Zhiqiang Wang, Yangkui Gu, Zhenhai Lu, Gong Chen, Peirong Ding, Xiaojun Wu, Zhizhong Pan, Desen Wan, Yuhong Li, Ruihua Xu, Yunfei Yuan* and Binkui Li*. Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis. World J Surg Oncol. 2020, 18;18(1):98.
  51. Song-Yang Li, Ying Zhu, Ruo-Nan Li, Jia-Hui Huang, Kai You, Yun-Fei Yuan*, and Shi-Mei Zhuang*. LncRNA Lnc-APUE is Repressed by HNF4�� and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis. Advanced Science 2021, 7(21):2001364. (2019 IF=15.840)
  52. Wei He, Baogang Peng, Yunqiang Tang, Junpin Yang, Yun Zheng, Jiliang Qiu, Ruhai Zou, Jingxian Shen, Binkui Li*, Yunfei Yuan*. Nomogram to Predict Survival of Patients with Recurrence of Hepatocellular Carcinoma After Surgery. Clinical Gastroenterology and Hepatology 2018, 16:756–764  (2018 IF=7.958)
  53. Wei He, Yun Zheng, Ruhai Zou, Jingxian Shen, Junpin Yang, Jiliang Qiu, Qiang Tao, Wenwu Liu, Zhiwen Yang, Yuanping Zhang, Binkui Li*, Yunfei Yuan*. Long- versus short-interval follow-up after resection of hepatocellular carcinoma: a retrospective cohort study. Cancer Communications (Lond). 2018, 38(1):26. (2018 IF=3.620)
  54. Qiang Tao, Wei He, Binkui Li, Yun Zheng,, Ruhai Zou, Jingxian Shen, Wenwu Liu, Yuanping Zhang, Yunfei Yuan*. Resection versus Resection with Preoperative Transcatheter Arterial Chemoembolization for Resectable Hepatocellular Carcinoma Recurrence. Journal of Cancer 2018, 9(16), 2778–2785. (2018 IF=3.182)
  55. Zhi-Wen Yang, Wei He, Yun Zheng, Ru-Hai Zou, Wen-Wu Liu, Yuan-Ping Zhang, Chen-Wei Wang, Yong-Jin Wang, Yi-Chuan Yuan, Bin-Kui Li*, Yun-Fei Yuan*. The efficacy and safety of long- versus short-interval transarterial chemoembolization in unresectable hepatocellular carcinoma. Journal of Cancer. 2018, 9(21):4000-4008. (2018 IF=3.182)
  56. Wenwu Liu, Yun Zheng, Wei He, Ruhai Zou, Jiliang Qiu, Jingxian Shen, Zhiwen Yang, Yuanping Zhang, Chenwei Wang, Yongjin Wang, Dinglan Zuo, Binkui Li*, Yunfei Yuan*. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Alimentary Pharmacology & Therapeutics 2018, 48(6):671-681. (2018 IF=7.731)
  57. Wenwu Liu, Yun Zheng, Ruhai Zou, Jingxian Shen, Wei He, Zhiwen Yang, Yuanping Zhang, Binkui Li* and Yunfei Yuan*. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018, 18:1186 (2018 IF=2.933)
  58. Jian-Hong Fang*, Zi-Jun Zhang, Li-Ru Shang, Yu-Wei Luo, Yi-Fang Lin, Yunfei Yuan*, and Shi-Mei Zhuang*. Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 2018, 68(4):1459-1475.  (2018 IF=14.971)
  59. Zhiwen Yang, Ruhai Zou, Yun Zheng, Jiliang Qiu, Jingxian Shen, Yadi Liao, Yuanping Zhang, Chenwei Wang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo & Wei He, Wenwu Liu, Binkui Li*, Yunfei Yuan*. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. European Radiology 2019. (2018 IF=3.962)
  60. Wenwu Liu, Zhiwen Yang, Ruhai Zou, Jiliang Qiu, Jingxian Shen, Yadi Liao, Chenwei Wang, Yuanping Zhang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo, Wei He, Yun Zheng*, Binkui Li*, Yunfei Yuan*. Resection vs Ablation for Multifocal Hepatocellular Carcinomas meeting the Barcelona-Clinic Liver Cancer A Classification: A Propensity Score Matching Study. Journal of Cancer 2019; 10(13):2857-2867. (2018 IF=3.182)
  61. Wenwu Liu, Ruhai Zou, Chenwei Wang, Jiliang Qiu, Jingxian Shen, Yadi Liao, Zhiwen Yang, Yuanping Zhang, Yongjin Wang, Yichuan Yuan, Kai Li, Dinglan Zuo, Wei He, Yun Zheng, Binkui Li and Yunfei Yuan*. Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis. Therapeutic Advances in Medical Oncology 2019, 11: 1–13 (2018 IF= 5.670)
  62. Chenwei Wang, Wei He, Yichuan Yuan, Yuanping Zhang, Kai Li, Ruhai Zou, Yadi Liao, Yongjin Wang,, Wenwu Liu,  Zhiwen Yang, Dinglan Zuo, Jiliang Qiu, Yun Zheng, Binkui Li*, Yunfei Yuan*. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy.  Liver International. 2020, 40(1):229-239 (2020 IF=5.828)
  63. Chenwei Wang, Yadi Liao, Jiliang Qiu, Yichuan Yuan, Yuanping Zhang, Kai Li,  Ruhai Zou1, Yongjin Wang, Dinglan Zuo, Wei He, Yun Zheng, Binkui Li*, Yunfei Yuan*. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. Journal of Cancer Research and Clinical Oncology 2020,146(10):2669-2680. (2020 IF=4.553)
  64. Yadi Liao, Chenwei Wang, Zhiwen Yang, Wenwu Liu, Yichuan Yuan, Kai Li, Yuanping Zhang, Yongjin Wang, Yunxing Shi, Yuxiong Qiu, Dinglan Zuo, Wei He, Jiliang Qiu, Xinyuan Guan, Yunfei Yuan*, Binkui Li*. Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma. Theranostics. 2020, 10(12):5209-5224.(2020 IF=11.556)
  65. Song-Yang Li, Ying Zhu, Ruo-Nan Li, Jia-Hui Huang, Kai You, Yun-Fei Yuan*, and Shi-Mei Zhuang*. LncRNA Lnc-APUE is Repressed by HNF4�� and Promotes G1/S Phase Transition and Tumor Growth by Regulating MiR-20b/E2F1 Axis. Advanced Science 2021, 8(7):2003094. (2021 IF=17.521)
  66. Chenwei Wang, Yadi Liao, Wei He, Hong Zhang, Dinglan Zuo, Wenwu Liu, Zhiwen Yang, Jiliang Qiu, Yichuan Yuan, Kai Li, Yuanping Zhang, Yongjin Wang, Yunxing Shi, Yuxiong Qiu, Song Gao, Yunfei Yuan*, Binkui Li*. Elafin promotes tumour metastasis and attenuates the anti-metastatic effects of erlotinib via binding to EGFR in hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2021, 40:113. (2021 IF=12.658).   
  67. Binkui Li, Jiliang Qiu, Yun Zheng, Yunxing Shi, Ruhai Zou, Wei He, Yichuang Yuan, Yuanping Zhang, Chenwei Wang, Zhiyu Qiu, Kai Li, Chengrui Zhong, Yunfei Yuan*. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma. Annals of Surgery Open. 2021, 2:e057.
  68. Yuanping Zhang, Jiliang Qiu, Dinglan Zuo, Yichuan Yuan, Yuxiong Qiu, Liang Qiao, Wei He, Binkui Li* and Yunfei Yuan*. SNRPC promotes hepatocellular carcinoma cell motility by inducing epithelial-mesenchymal transition. FEBS Open Bio. 2021;11(6):1757-70. (2021 IF=2.792)
  69. Zhiyu Qiu, Lujun Shen1, Yiquan Jiang, Jiliang Qiu, Zining Xu, Mengting Shi, Zhentao Yu, Yanping Ma, Wei He, Yun Zheng, Binkui Li, Guoying Wang*, Yunfei Yuan*. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Annals of Translational Medicine 2021, 9(4):283.
  70. Chengrui Zhong, Yi Niu, Wenwu Liu, Yichuan Yuan, Kai Li, Yunxing Shi, Zhiyu Qiu, Keren Li, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Zhiwen Yang, Yadi Liao, Yuanping Zhang, Chenwei Wang, Jiliang Qiu, Wei He, Yunfei Yuan* and Binkui Li*. S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression. Advanced Science 2022,9:2202206. 
  71. Kai Li, Yi Niu, Yichuan Yuan, Jiliang Qiu, Yunxing Shi, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhenkun Huang, Chao Zhang, Dinglan Zuo, Wei He, Yunfei Yuan* and Binkui Li*. Insufficient ablation induces E3-ligase Nedd4 to promote hepatocellular carcinoma progression by tuning TGF-β signaling. Oncogene 2022, 41:3197–3209;
  72. Yuanping Zhang, Dinglan Zuo, Jiliang Qiu, Kai Li, Yi Niu, Yichuan Yuan, Yuxiong Qiu, Liang Qiao, Wei He, Chenwei Wang, Yunfei Yuan* and Binkui Li*. NXN suppresses metastasis of hepatocellular carcinoma by promoting degradation of Snail through binding to DUB3. Cell Death Disease. 2022, 13(8):676. 
  73. Cheng-Rui Zhong, Ji-Liang Qiu, Yi-Chuan Yuan, Zhi-Yu Qiu, Kai Li, Chen-Wei Wang, Yun-Xing Shi, Ke-Ren Li, Zhu Lin, Zhen-Kun Huang, Wei He, Bin-Kui Li*, Yun-Fei Yuan*. A detailed assessment of liver function in patients with hepatocellular carcinoma via the modified albumin-bilirubin (mALBI) grade. American Journal of Cancer Research. 2022,15;12(6):2711-2720
  74. Feihu Xie, Meiheban Bazhabayi, Binkui Li*, Yunfei Yuan*. (Letter) Insight into the gut microbiome dysbiosis in patients with liver failure after extended-hepatectomy. Annals of Translational Medicine 2022;10(21):1186
  75. Yichuan Yuan, Wei He, Zhiwen Yang, Jiliang Qiu, Zhenkun Huang, Yunxing Shi, Zhu Lin, Yun Zheng, Minshan Chen, Wan Yee Lau, Binkui Li*, Yunfei Yuan*. TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score matching study. International Journal of Surgery 2023, 109:1222–1230
  76. Wei He, Binkui Li, Yunfei Yuan*. Editorial: is microwave ablation an alternative to liver resection for hepatocellular carcinoma? Alimentary Pharmacology & Therapeutics 2023, 57(1):173-174.
  77. Yunxing Shi, Yi Niu, Yichuan Yuan, Kai Li, Chengrui Zhong, Zhiyu Qiu, Keren Li, Zhu Lin, Zhiwen Yang, Dinglan Zuo, Jiliang Qiu1,2, Wei He, Chenwei Wang, Yadi Liao, Guocan Wang*, Yunfei Yuan* & Binkui Li*. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver cancer. Nature Communications 2023, 6;14(1):1932.
  78. Keren Li, Yi Niu, Kai Li, Chengrui Zhong, Zhiyu Qiu, Yichuan Yuan, Yunxing Shi, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Yunfei Yuan* and Binkui Li*. Dysregulation of PLOD2 Promotes Tumor Metastasis and Invasion in Hepatocellular Carcinoma. Journal of Clinical and Translational Hepatology 2023, 11(5):1094-1105.
  79. Zhiyu Qiu, Chenwei Wang, Pinzhu Huang, Yichuan Yuan, Yunxing Shi, Zhu Lin, Zhenkun Huang, Dinglan Zuo, Jiliang Qiu, Wei He, Jingxian Shen, Yi Niu*, Yunfei Yuan*, Binkui Li*. RFX6 facilitates aerobic glycolysis-mediated growth and metastasis of hepatocellular carcinoma through targeting PGAM1. Clinical and Translational Medicine 2023, 13:e1511.
  80. De-Shen Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan*, Rui-Hua Xu*, Yu-Hong Li*. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-typepatients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLOS Medicine 2024, 21(5): e1004389. (2023 IF=10.5)
  81. Zhu Lin, Zhenkun Huang, Jiliang Qiu, Yunxing Shi, Dinglan Zuo, Zhiyu Qiu, Wei He, Yi Niu*, Yunfei Yuan* and Binkui Li*. m6Amediated lncOXAR promotes oxaliplatin resistance by enhancing Ku70 stability in nonalcoholic steatohepatitisrelated hepatocellular carcinoma. Journal of Experimental & Clinical Cancer Research 2024, 43:206
  82. Binkui Li*, Chenwei Wang, Wei He, Jiliang Qiu, Yun Zheng, Ruhai Zou, Zhu Lin, Yunxing Shi, Yichuan Yuan, Rong Zhang, Chao Zhang, Minshan Chen, Wan Yee Lau, Yunfei Yuan*. Watch-and-wait strategy vs. resection in patients with radiologic complete response after conversion therapy for initially unresectable hepatocellular carcinoma: a propensity score-matching comparative study. International Journal of Surgery 2024, 110:2545–2555.
  83. Yunxing Shi, Zongfeng Wu, Shaoru Liu, Dinglan Zuo, Yi Niu, Yuxiong Qiu, Liang Qiao, Wei He, Jiliang Qiu, Yunfei Yuan*, Guocan Wang* & Binkui Li*. Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost antitumor immunity by activating cGAS/STING signaling. Nature Communications 2024, 15:7930.
  84. Yichuan Yuan, Hong Peng, Wei He, Yun Zheng, Jiliang Qiu, Bin Chen, Ruhai Zou, Chenwei Wang, Wan Yee Lau, Binkui Li*, Yunfei Yuan*. Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial. Cancer Communications 2024, 44(11):1337-1349

 

    奖励与科技成果：

    1. Young Investigator Award, 2006 Shanghai-Hong Kong International Liver Congress (2006沪港国际肝病会议), Shanghai Organizing Committee & Cheng Si Yuan(China-International) Hepatitis Research Foundation, 25th-28th March, 2006.
    2. 项目名称：分子标志物在消化系统肿瘤个体化诊疗中的应用研究，2018年度教育部科学技术进步奖一等奖，证书号: 2018-209，奖励日期：2019年1月15日，获奖者：徐瑞华、元云飞、韦玮、王峰、关新元、鞠怀强、贾卫华、康铁邦、赵明、邵建永、张东生、邱妙珍、金颖、王德深、鲁运新
    3. 项目名称：消化系统肿瘤分子标志物的发现和临床应用, 2019年度国家科学技术进步奖二等奖, 证书号：2019-J-233-2-05-R05，奖励日期：2019年12月18日，获奖者：徐瑞华、王峰、骆卉妍、关新元、元云飞、云径平、康铁邦、邵建永、鞠怀强、邱妙珍。

     

    创建日期：2002年9月28日

    更新日期：2025年3月28日